Topical Ruxolitinib Effective for Vitiligo in Adolescents
Ruxolitinib cream is under review at the US Food and Drug Administration for treating vitiligo in patients ages 12 years and older; the agency is expected to make a decision by July 18.
Medscape Medical News
source https://www.medscape.com/viewarticle/976781?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/976781?src=rss
Comments
Post a Comment